Moderna applies for emergency FDA approval for its coronavirus vaccine

Moderna announced Monday it has applied to FDA for emergency use authorization of its candidate COVID-19 vaccine. If approved, the company said, vaccinations could begin in the United States as soon as December 21. Moderna reported that complete data from a large study indicated the vaccine was 94.1% effective, confirming earlier estimates.

Moderna announced Monday it has applied to FDA for emergency use authorization of its candidate COVID-19 vaccine. If approved, the company said, vaccinations could begin in the United States as soon as December 21. Moderna reported that complete data from a large study indicated the vaccine was 94.1% effective, confirming earlier estimates. Additionally, the data found the vaccine—which was developed in collaboration with researchers at the National Institute of Allergy and Infectious Diseases—was 100% effective at preventing severe coronavirus infection. In an interview, Moderna CEO Stéphane Bancel said the company was "on track" to produce 20 million vaccine doses by the end of the year, and from 500 million to 1 billion doses in 2021. Vaccination requires two doses, administered 1 month apart. Pfizer submitted an application for emergency use authorization of its COVID-19 vaccine, which also requires two doses per person, on November 20. A panel of CDC advisers is set to meet Tuesday to decide how to allocate initial supplies of COVID-19 vaccine.